Brainstorm Cell Therapeutics Inc.
BCLI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $849 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $240 | $265 | $285 | $260 |
| Gross Profit | $849 | -$265 | -$285 | -$260 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $4,411 | $10,481 | $13,956 | $15,235 |
| G&A Expenses | $7,042 | $10,693 | $10,866 | $9,304 |
| SG&A Expenses | $7,042 | $10,693 | $10,866 | $9,304 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11,453 | $21,174 | $24,822 | $24,539 |
| Operating Income | -$11,693 | -$21,439 | -$24,822 | -$24,539 |
| % Margin | -1,377.3% | – | – | – |
| Other Income/Exp. Net | $70 | $4,247 | $545 | $82 |
| Pre-Tax Income | $11,623 | -$17,192 | -$24,277 | -$24,457 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $11,623 | -$17,192 | -$24,277 | -$24,457 |
| % Margin | 1,369% | – | – | – |
| EPS | 2.19 | -4.48 | -9.93 | -10.09 |
| % Growth | 148.9% | 54.9% | 1.6% | – |
| EPS Diluted | 2.19 | -4.48 | -9.93 | -10.09 |
| Weighted Avg Shares Out | 5,310 | 3,839 | 2,445 | 2,425 |
| Weighted Avg Shares Out Dil | 5,310 | 3,839 | 2,445 | 2,425 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $545 | $82 |
| Interest Expense | $77 | $0 | $0 | $0 |
| Depreciation & Amortization | $240 | $265 | $285 | $260 |
| EBITDA | -$11,306 | -$16,927 | -$23,992 | -$24,279 |
| % Margin | -1,331.7% | – | – | – |